David Planchard
Gustave Roussy, Cancer Campus, Grand Paris · Gustave Roussy (Villejuif - France) · Intergroupe Francophone de Cancerologie Thoracique
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Planchard as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:24 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07360743 · Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 LevelsUNICANCER · recruiting · Non Small Cell Lung Cancer (Squamous or Non Squamous) · principal investigator
- Ph2NCT04940325 · Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung CancerGustave Roussy, Cancer Campus, Grand Paris · active not recruiting · Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer, Unresectable Non-small Lung Cancer · study chair
- Ph2NCT04526782 · ENCOrafenib With Binimetinib in bRAF NSCLCIntergroupe Francophone de Cancerologie Thoracique · active not recruiting · Non Small Cell Lung Cancer, BRAF V600E · principal investigator
- Ph2NCT04233021 · Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR MutationIntergroupe Francophone de Cancerologie Thoracique · completed · Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases · principal investigator
- Ph3NCT04035486 · A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)AstraZeneca · active not recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph1NCT02040064 · Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC PatientsGustave Roussy, Cancer Campus, Grand Paris · completed · Non Small Cell Lung Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 15:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 15:24 UTC. The ranking covers the 200 most relevant of 60 PubMed records, and a shared surname and initials can bring in a namesake. All 60 on PubMed
- Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.N Engl J Med · 20184,615 citationsRCR 168.8
- Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.N Engl J Med · 20173,900 citationsRCR 133.1
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.N Engl J Med · 20202,543 citationsRCR 114.6
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.N Engl J Med · 20182,335 citationsRCR 81.4
- AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.N Engl J Med · 20151,776 citationsRCR 54.0
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.J Clin Oncol · 20221,268 citationsRCR 88.1
- 1,217 citationsRCR 34.7
- Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.N Engl J Med · 2022890 citationsRCR 60.8
- Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.Lancet Oncol · 2017767 citationsRCR 23.4
- Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.N Engl J Med · 2023709 citationsRCR 61.0